Literature DB >> 7615542

Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor.

A Higazi1, R L Cohen, J Henkin, D Kniss, B S Schwartz, D B Cines.   

Abstract

Single-chain urokinase (scuPA), the unique form of urokinase secreted by cells, is converted to an active two-chain molecule through the cleavage of a single peptide bond by plasmin and other specific proteinases. Although scuPA may express limited enzymatic activity, its contribution to plasminogen activation on cell surfaces remains uncertain. Further, although it is well known that scuPA binds to a specific extracellular urokinase-type plasminogen activator receptor, the effect of this interaction on the enzymatic activity of scuPA has not been described. In the present paper we report that the binding of scuPA to cellular an to recombinant soluble urokinase-type plasminogen activator receptors (suPAR) increases its catalytic activity as measured by the cleavage of a urokinase-specific chromogenic substrate. suPAR increased the Vmax of scuPA 5-fold with little change in its Km. suPAR also stimulated the plasminogen activator activity of scuPA by decreasing its Km for Glu-plasminogen from 1.15 microM to 0.022 microM and by increasing the kcat of this reaction from 0.0015 to 0.022 s-1. Preincubation of scuPA with suPAR also enhances its susceptibility to inhibition by plasminogen activator inhibitor type 1, consistent with exposure of its catalytic site. The activity of scuPA bound to suPAR is not accompanied by cleavage of scuPA, which continues to migrate as a single band in SDS-polyacrylamide gel electrophoresis under reducing conditions. Moreover, suPAR increases the plasminogen activator activity of a plasmin-insensitive variant, scuPA (scuPA-Glu158), as well. Enhancement of scuPA activity by suPAR is both prevented and reversed by its aminoterminal fragment (amino acids 1-135), which competes for receptor binding, suggesting that continued binding to the receptor is required for expression of scuPA's enzymatic activity. Thus, our data suggest that scuPA may undergo a reversible transformation between a latent and an active state. The urokinase receptor may induce or stabilize scuPA in its active conformation, thereby contributing to the initiation of plasminogen activation on cell surfaces.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7615542     DOI: 10.1074/jbc.270.29.17375

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Inhibition of Human Urokinase-Type Plasminogen Activator (uPA) Enzyme Activity and Receptor Binding by DNA Aptamers as Potential Therapeutics through Binding to the Different Forms of uPA.

Authors:  Nico Dreymann; Julia Wuensche; Wiebke Sabrowski; Anja Moeller; Denise Czepluch; Dana Vu Van; Susanne Fuessel; Marcus M Menger
Journal:  Int J Mol Sci       Date:  2022-04-28       Impact factor: 6.208

2.  The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.

Authors:  Niels Behrendt; Karin List; Peter A Andreasen; Keld Danø
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

3.  Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile.

Authors:  Juan-Carlos Murciano; Abd Al-Roof Higazi; Douglas B Cines; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2009-07-16       Impact factor: 9.776

4.  Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis.

Authors:  H Allgayer; H Wang; S Shirasawa; T Sasazuki; D Boyd
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

5.  Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery.

Authors:  Susanna W L de Geus; Leonora S F Boogerd; Rutger-Jan Swijnenburg; J Sven D Mieog; Willemieke S F J Tummers; Hendrica A J M Prevoo; Cornelis F M Sier; Hans Morreau; Bert A Bonsing; Cornelis J H van de Velde; Alexander L Vahrmeijer; Peter J K Kuppen
Journal:  Mol Imaging Biol       Date:  2016-12       Impact factor: 3.488

Review 6.  Fibrinolytic Serine Proteases, Therapeutic Serpins and Inflammation: Fire Dancers and Firestorms.

Authors:  Jordan R Yaron; Liqiang Zhang; Qiuyun Guo; Shelley E Haydel; Alexandra R Lucas
Journal:  Front Cardiovasc Med       Date:  2021-03-25

Review 7.  Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.

Authors:  Niaz Mahmood; Catalin Mihalcioiu; Shafaat A Rabbani
Journal:  Front Oncol       Date:  2018-02-12       Impact factor: 6.244

8.  Pleural Fluid suPAR Levels Predict the Need for Invasive Management in Parapneumonic Effusions.

Authors:  David T Arnold; Fergus W Hamilton; Karen T Elvers; Stuart W Frankland; Natalie Zahan-Evans; Sonia Patole; Andrew Medford; Rahul Bhatnagar; Nicholas A Maskell
Journal:  Am J Respir Crit Care Med       Date:  2020-06-15       Impact factor: 21.405

9.  suPAR Surprises as a Biomarker of Invasive Outcomes in Pleural Infection.

Authors:  Steven Idell; Y C Gary Lee
Journal:  Am J Respir Crit Care Med       Date:  2020-06-15       Impact factor: 21.405

10.  Moscatilin Inhibits Metastatic Behavior of Human Hepatocellular Carcinoma Cells: A Crucial Role of uPA Suppression via Akt/NF-κB-Dependent Pathway.

Authors:  Chen-Lin Yu; Meng-Shih Weng; Wei-Cheng Chen; Kai-Ting Chien; Chih-Wen Chi; Ching-Hu Chung; Chia-Wen Huang; Po-Chuan Wang; Chien-Chih Chen; An-Chi Tsai; Shih-Chia Liu; Shih-Wei Wang
Journal:  Int J Mol Sci       Date:  2021-03-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.